- Home
- MOGU vs SNTI Comparison
MOGU vs SNTI Comparison
Compare MOGU & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOGU | SNTI |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 29.8M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MOGU | SNTI |
|---|---|---|
| Price | $2.12 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 6.9K | ★ 187.9K |
| Earning Date | 01-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.83 | $0.77 |
| 52 Week High | $8.10 | $3.88 |
Technical Indicators
Market Signals| Indicator | MOGU | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 53.04 |
| Support Level | $2.06 | $0.81 |
| Resistance Level | $2.57 | $1.02 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 18.87 | 67.32 |
Price Performance
Historical ComparisonAbout MOGU MOGU Inc.
MOGU Inc is an online service provider in China, operating a KOL-driven online fashion and lifestyle platform, Mogujie, and providing customized online branding solutions to businesses. The company, on its platform, provides content related to fashion and lifestyle guides in various multimedia formats, which include Live Video Broadcasts, Short-form Videos, Photography, and an Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology, and other relevant services to merchants and users, as well as technology services to brand owners.
About SNTI Senti Biosciences Inc.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).